Cross-source evidence timeline

Pegcetacoplan research timeline

Follow 51 selected, directly cited source records from October 6, 2020 through November 13, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

51Selected records
7Source years
3Evidence lanes
November 13, 2026Latest source date

Source year

2026

30 records
  1. Literature metadata

    Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.↗

    PubMed lists PMID 43024395 in Journal of the American Society of Nephrology : JASN as Journal Article, with publication-date metadata of 2026-11-13 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT06722157↗

    PeptideScanner retained ClinicalTrials.gov record NCT06722157 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03531255↗

    PeptideScanner retained ClinicalTrials.gov record NCT03531255 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  4. Literature metadata

    Pegcetacoplan for geographic atrophy: Bridging the "clinical relevance gap" through precision medicine.↗

    PubMed lists PMID 42998772 in Survey of ophthalmology as Journal Article, Review, with publication-date metadata of 2026-11-07 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07898774↗

    PeptideScanner retained ClinicalTrials.gov record NCT07898774 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  6. Literature metadata

    Mixed Intravascular and Extravascular Hemolysis Despite Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case of Switching to Pegcetacoplan.↗

    PubMed lists PMID 42972953 in Turkish journal of haematology : official journal of Turkish Society of Haematology as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study.↗

    PubMed lists PMID 42930807 in Journal of personalized medicine as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy.↗

    PubMed lists PMID 42898424 in Kidney international reports as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Podocyte and tubular vacuolization in patients receiving pegcetacoplan.↗

    PubMed lists PMID 42800616 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-09-26 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham.↗

    PubMed lists PMID 39497616 in CPT: pharmacometrics & systems pharmacology as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-11-05 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT07746895↗

    PeptideScanner retained ClinicalTrials.gov record NCT07746895 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT05776472↗

    PeptideScanner retained ClinicalTrials.gov record NCT05776472 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  13. Literature metadata

    Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.↗

    PubMed lists PMID 39656072 in Expert review of hematology as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  14. Literature metadata

    Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.↗

    PubMed lists PMID 42133432 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  15. Literature metadata

    Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.↗

    PubMed lists PMID 38722644 in JAMA ophthalmology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  16. Literature metadata

    Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.↗

    PubMed lists PMID 42138781 in Advances in therapy as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-05-15 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  17. Literature metadata

    Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.↗

    PubMed lists PMID 40833323 in Investigative ophthalmology & visual science as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  18. Clinical trials

    ClinicalTrials.gov record NCT07214298↗

    PeptideScanner retained ClinicalTrials.gov record NCT07214298 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  19. Literature metadata

    Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria.↗

    PubMed lists PMID 42022788 in EJHaem as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  20. Literature metadata

    Pegcetacoplan prophylaxis for recurrent C3 glomerulopathy with multifactorial genetic background.↗

    PubMed lists PMID 42061561 in Kidney international as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  21. Clinical trials

    ClinicalTrials.gov record NCT07160179↗

    PeptideScanner retained ClinicalTrials.gov record NCT07160179 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  22. Clinical trials

    ClinicalTrials.gov record NCT04901936↗

    PeptideScanner retained ClinicalTrials.gov record NCT04901936 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  23. Clinical trials

    ClinicalTrials.gov record NCT06161584↗

    PeptideScanner retained ClinicalTrials.gov record NCT06161584 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-06-01, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  24. Clinical trials

    ClinicalTrials.gov record NCT07495722↗

    PeptideScanner retained ClinicalTrials.gov record NCT07495722 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  25. Clinical trials

    ClinicalTrials.gov record NCT04572854↗

    PeptideScanner retained ClinicalTrials.gov record NCT04572854 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  26. Clinical trials

    ClinicalTrials.gov record NCT05809531↗

    PeptideScanner retained ClinicalTrials.gov record NCT05809531 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  27. Clinical trials

    ClinicalTrials.gov record NCT04919629↗

    PeptideScanner retained ClinicalTrials.gov record NCT04919629 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  28. Literature metadata

    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.↗

    PubMed lists PMID 41337715 in The New England journal of medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2025-12-04 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  29. Clinical trials

    ClinicalTrials.gov record NCT05067127↗

    PeptideScanner retained ClinicalTrials.gov record NCT05067127 at 2026-11-16T01:37:14.654Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  30. Literature metadata

    Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.↗

    PubMed lists PMID 36965105 in European journal of haematology as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2023-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

5 records
  1. Clinical trials

    ClinicalTrials.gov record NCT05148299↗

    PeptideScanner retained ClinicalTrials.gov record NCT05148299 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05096403↗

    PeptideScanner retained ClinicalTrials.gov record NCT05096403 at 2026-11-16T01:37:14.654Z. Its registry update date was 2025-10-30, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  3. Literature metadata

    Treatment of geographic atrophy: an update on data related to pegcetacoplan.↗

    PubMed lists PMID 37815317 in Current opinion in ophthalmology as Review, Journal Article, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.↗

    PubMed lists PMID 40280279 in American journal of ophthalmology as Journal Article, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2025-04-23 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.↗

    PubMed lists PMID 38727860 in Drugs in R&D as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, with publication-date metadata of 2024-05-10 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

3 records
  1. Literature metadata

    Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.↗

    PubMed lists PMID 38593241 in Blood advances as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-11 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.↗

    PubMed lists PMID 38453703 in Annals of hematology as Journal Article, Clinical Trial, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function.↗

    PubMed lists PMID 39201278 in International journal of molecular sciences as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2023

6 records
  1. Literature metadata

    Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration.↗

    PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2023-26255↗

    The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.↗

  3. Literature metadata

    Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.↗

    PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT03525613↗

    PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  5. Literature metadata

    WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy.↗

    PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Drugs@FDA application NDA217171↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients.↗

Source year

2022

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT03500549↗

    PeptideScanner retained ClinicalTrials.gov record NCT03500549 at 2026-11-16T01:37:14.654Z. Its registry update date was 2022-03-25, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

Source year

2021

3 records
  1. Regulatory

    Drugs@FDA application NDA215014↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 215014 with status AP dated 2021-05-14, and names pegcetacoplan among the application record's active ingredients.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02588833↗

    PeptideScanner retained ClinicalTrials.gov record NCT02588833 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-11, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02264639↗

    PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

Source year

2020

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT03593200↗

    PeptideScanner retained ClinicalTrials.gov record NCT03593200 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-12-22, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02461771↗

    PeptideScanner retained ClinicalTrials.gov record NCT02461771 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02503332↗

    PeptideScanner retained ClinicalTrials.gov record NCT02503332 at 2026-11-16T01:37:14.654Z. Its registry update date was 2020-10-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.↗